Study of lutikizumab for hidradenitis suppurativa or eczema
Treatments studied
Part of Genetic & congenital, Immune system & allergy, Infections, Skin clinical trials.
This study tests an investigational medicine called lutikizumab, given as shots under the skin, for people with moderate-to-severe hidradenitis suppurativa (HS) or atopic dermatitis (eczema). It looks at how the medicine affects skin changes and may help if other treatments haven’t worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have moderate-to-severe hidradenitis suppurativa (HS) for at least 6 months, or moderate-to-severe atopic dermatitis (eczema) that started more than 1 year ago.
- If you have HS, you can be new to biologic treatments or you may have tried an anti-TNF medicine (like adalimumab) for at least 12 weeks and it didn’t work or stopped working.
- If you have eczema, you can be new to biologic treatments or you may have tried dupilumab (Dupixent) for at least 8 weeks and it didn’t work or stopped working.
- You cannot have had any cancer (except certain skin cancers) in the past 5 years.
- You cannot have another active skin disease (like an infection) that could interfere with study assessments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called LAD191 for people with moderate to severe hidradenitis suppurativa (HS) who haven't been helped enough by antibiotics. Researchers want to see if LAD191 safely reduces painful bumps and tunnels.
This study tests an injected drug called siplizumab for people with moderate to severe hidradenitis suppurativa (HS) that hasn't improved with other treatments. The goal is to see if it safely reduces painful bumps and improves your skin condition.
This trial tests a new medicine called HB0043 for people with moderate to severe hidradenitis suppurativa (a skin condition causing painful lumps). It aims to see if the drug is safe and helps reduce symptoms.
This study tracks how secukinumab (a new medication) works for hidradenitis suppurativa—a painful skin condition with recurring boils and abscesses—in real-world patient care in Italy. Researchers want to understand treatment patterns and outcomes to help improve care for this condition.
This study tests a new drug called LAD328 for hidradenitis suppurativa (HS), a chronic skin condition with painful lumps and abscesses. The trial is looking for adults with moderate-to-severe HS who haven't responded well to antibiotics to see if this new treatment can help reduce symptoms.
This study tests a cream called ruxolitinib for people with hidradenitis suppurativa (HS). The goal is to see how much of the cream is absorbed when it's applied to a large area of the body.
Hear when a new Hidradenitis Suppurativa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.